International expert consensus on immunotherapy for early-stage non-small cell lung cancer

CATO consensus group

doi:10.21037/tlcr-22-617

International expert consensus on immunotherapy for early-stage non-small cell lung cancer

CATO consensus group

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	1742-1762
Number of pages	21
Journal	Translational Lung Cancer Research
Volume	11
Issue number	9
DOIs	https://doi.org/10.21037/tlcr-22-617
State	Published - Sep 2022
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.21037/tlcr-22-617

Cite this

@article{6e62d5d08d4a4e19b186fd4d3a15eece,

title = "International expert consensus on immunotherapy for early-stage non-small cell lung cancer",

author = "{CATO consensus group} and Wenhua Liang and Kaican Cai and Qingdong Cao and Chun Chen and Haiquan Chen and Jun Chen and Chen, {Ke Neng} and Qixun Chen and Tianqing Chu and Yuchao Dong and Jiang Fan and Wentao Fang and Junke Fu and Xiangning Fu and Shugeng Gao and Di Ge and Guojun Geng and Qing Geng and Jie He and Jian Hu and Jie Hu and Hu, {Wei Dong} and Feng Jiang and Tao Jiang and Wenjie Jiao and Li, {He Cheng} and Qiang Li and Shanqing Li and Shuben Li and Xiangnan Li and Liao, {Yong De} and Changhong Liu and Hongxu Liu and Yang Liu and Zhuming Lu and Qingquan Luo and Haitao Ma and Xiaojie Pan and Guibin Qiao and Shengxiang Ren and Weiyu Shen and Yong Song and Daqiang Sun and Guangsuo Wang and Jie Wang and Mengzhao Wang and Qiwen Wang and Wang, {Wen Xiang} and Mok, {Tony S.K.} and Tina Cascone",

note = "Funding Information: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups. com/article/view/10.21037/tlcr-22-617/coif). TH serves as an unpaid editorial board member of Translational Lung Cancer Research from January 2022 to December 2023. AR serves as an unpaid editorial board member of Translational Lung Cancer Research from November 2020 to October 2022. RAR serves as an unpaid editorial board member of Translational Lung Cancer Research from January 2022 to December 2023. MP serves as an unpaid editorial board member of Translational Lung Cancer Research from October 2021 to September 2023. RAR has been a consultant for Amgen, Ipsen Biopharmaceuticals, Novartis, Advanced Accelerator Applications, Curium Pharma, EMD Serono, Astra-Zeneca. He has also received research funding (to institution) from Merck & Co and Aadi Biosciences. He is also on the speaker bureaus for Ipsen Biopharmaceuticals and Astra-Zeneca. Mariano Provencio received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and consulting fees from BMS, Astra Z{\'e}neca, MSD, Roche, Takeda and Pfizer. Jay M. Lee reports advisory board/consultant of Astrazeneca, Bristol Myers Squibb, Genentech, Novartis, Roche; research support from Genentech, Novartis; steering committee of Genentech, Novartis; speaker{\textquoteright}s bureau of AstraZeneca, Genentech, Roche; stock from Moderna; patents of UCLA. Antonio Passaro received honoraria for consulting, advisory role or lectures from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Jansenn, Merck Sharp & Dohme, Roche Genentech, Novartis, MundiPharma, Daiichi Sankyo, eCancer and Medscape. TC reports speaker fees/honoraria from The Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape, and PeerView; travel, food and beverage expenses from Dava Oncology; advisory role/ consulting fees from AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co., Genentech, and Arrowhead Pharmaceuticals; and institutional research funding from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim and EMD Serono. The other authors have no conflicts of",

year = "2022",

month = sep,

doi = "10.21037/tlcr-22-617",

language = "English (US)",

volume = "11",

pages = "1742--1762",

journal = "Translational Lung Cancer Research",

issn = "2218-6751",

publisher = "Society for Translational Medicine (STM)",

number = "9",

}

TY - JOUR

T1 - International expert consensus on immunotherapy for early-stage non-small cell lung cancer

AU - CATO consensus group

AU - Liang, Wenhua

AU - Cai, Kaican

AU - Cao, Qingdong

AU - Chen, Chun

AU - Chen, Haiquan

AU - Chen, Jun

AU - Chen, Ke Neng

AU - Chen, Qixun

AU - Chu, Tianqing

AU - Dong, Yuchao

AU - Fan, Jiang

AU - Fang, Wentao

AU - Fu, Junke

AU - Fu, Xiangning

AU - Gao, Shugeng

AU - Ge, Di

AU - Geng, Guojun

AU - Geng, Qing

AU - He, Jie

AU - Hu, Jian

AU - Hu, Jie

AU - Hu, Wei Dong

AU - Jiang, Feng

AU - Jiang, Tao

AU - Jiao, Wenjie

AU - Li, He Cheng

AU - Li, Qiang

AU - Li, Shanqing

AU - Li, Shuben

AU - Li, Xiangnan

AU - Liao, Yong De

AU - Liu, Changhong

AU - Liu, Hongxu

AU - Liu, Yang

AU - Lu, Zhuming

AU - Luo, Qingquan

AU - Ma, Haitao

AU - Pan, Xiaojie

AU - Qiao, Guibin

AU - Ren, Shengxiang

AU - Shen, Weiyu

AU - Song, Yong

AU - Sun, Daqiang

AU - Wang, Guangsuo

AU - Wang, Jie

AU - Wang, Mengzhao

AU - Wang, Qiwen

AU - Wang, Wen Xiang

AU - Mok, Tony S.K.

AU - Cascone, Tina

N1 - Funding Information: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups. com/article/view/10.21037/tlcr-22-617/coif). TH serves as an unpaid editorial board member of Translational Lung Cancer Research from January 2022 to December 2023. AR serves as an unpaid editorial board member of Translational Lung Cancer Research from November 2020 to October 2022. RAR serves as an unpaid editorial board member of Translational Lung Cancer Research from January 2022 to December 2023. MP serves as an unpaid editorial board member of Translational Lung Cancer Research from October 2021 to September 2023. RAR has been a consultant for Amgen, Ipsen Biopharmaceuticals, Novartis, Advanced Accelerator Applications, Curium Pharma, EMD Serono, Astra-Zeneca. He has also received research funding (to institution) from Merck & Co and Aadi Biosciences. He is also on the speaker bureaus for Ipsen Biopharmaceuticals and Astra-Zeneca. Mariano Provencio received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and consulting fees from BMS, Astra Zéneca, MSD, Roche, Takeda and Pfizer. Jay M. Lee reports advisory board/consultant of Astrazeneca, Bristol Myers Squibb, Genentech, Novartis, Roche; research support from Genentech, Novartis; steering committee of Genentech, Novartis; speaker’s bureau of AstraZeneca, Genentech, Roche; stock from Moderna; patents of UCLA. Antonio Passaro received honoraria for consulting, advisory role or lectures from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Jansenn, Merck Sharp & Dohme, Roche Genentech, Novartis, MundiPharma, Daiichi Sankyo, eCancer and Medscape. TC reports speaker fees/honoraria from The Society for Immunotherapy of Cancer, Bristol Myers Squibb, Roche, Medscape, and PeerView; travel, food and beverage expenses from Dava Oncology; advisory role/ consulting fees from AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck & Co., Genentech, and Arrowhead Pharmaceuticals; and institutional research funding from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim and EMD Serono. The other authors have no conflicts of

PY - 2022/9

Y1 - 2022/9

UR - http://www.scopus.com/inward/record.url?scp=85139829700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139829700&partnerID=8YFLogxK

U2 - 10.21037/tlcr-22-617

DO - 10.21037/tlcr-22-617

M3 - Article

C2 - 36248334

AN - SCOPUS:85139829700

SN - 2218-6751

VL - 11

SP - 1742

EP - 1762

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

IS - 9

ER -

International expert consensus on immunotherapy for early-stage non-small cell lung cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this